
    
      Patients will receive 2 dosing regimens of GW433908/RTV or LPV/RTV, in combination with 2
      active RTIs, after failing their first or second protease inhibitor-containing regimen.
      Patients are required to be on therapy at time of screening and must remain on this therapy
      until Day 1.
    
  